NCT00074074 - Infliximab in Treating Patients With Myelodysplastic Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

December 31, 2006

Conditions

Myelodysplastic Syndromes

Interventions

BIOLOGICAL

infliximab

Trial Locations (19)

1000

Institut Jules Bordet, Brussels

1070

Hopital Universitaire Erasme, Brussels

8000

AZ Sint-Jan, Bruges

8800

H. Hartziekenhuis - Roeselaere., Roeselare

70199

Marienhospital Stuttgart, Stuttgart

75181

Hotel Dieu de Paris, Paris

B-2650

Universitair Ziekenhuis Antwerpen, Edegem

B-3000

U.Z. Gasthuisberg, Leuven

B-4800

Centre Hospitalier Peltzer-La Tourelle, Verviers

775 20

University Hospital - Olomouc, Olomouc

128 20

Institute of Hematology and Blood Transfusion, Prague

06189

Centre Antoine Lacassagne, Nice

D-69117

Ruprecht - Karls - Universitaet Heidelberg, Heidelberg

D-72076

Southwest German Cancer Center at Eberhard-Karls-University, Tübingen

I-61100

Ospedale San Salvatore, Pesaro

1007 MB

Vrije Universiteit Medisch Centrum, Amsterdam

2300 RC

Leiden University Medical Center, Leiden

NL-6500 HB

Universitair Medisch Centrum St. Radboud - Nijmegen, Nijmegen

2597AX

Ziekenhuis Bronovo, The Hague

All Listed Sponsors

lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK